Regorafenib Not Cost-effective for Third-line Treatment of Colorectal Cancer

Share this content:
Regorafenib for third-line management of metastatic colorectal cancer may provide minimal incremental benefit at high incremental cost.
Regorafenib for third-line management of metastatic colorectal cancer may provide minimal incremental benefit at high incremental cost.

Regorafenib for third-line management of metastatic colorectal cancer may provide minimal incremental benefit at high incremental cost per quality-adjust life-years (QALY), according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Researchers led by Daniel Goldstein, MD, of Emory University developed a Markov model in order to compare the cost-effectiveness of regorafenib compared to placebo in these patients.

“Regorafenib is a standard-care option for treatment-refractory metastatic colorectal cancer that increases median overall survival by six weeks compared with placebo,” the authors noted.

They measured health outcomes in life-years and QALYs, and used Medicare reimbursement rates in 2014 to measure drug costs.

They found that regorafenib provided an additional 0.04 QALYs (0.13 life-years) at a cost of 40,000 dollars, which translated to an incremental cost-effectiveness ratio of 900,000 dollars per QALY.

RELATED: Risk Stratification Could Make Colorectal Cancer Screening More Efficient

Upon univariable and probabilistic sensitivity analyses, incremental cost-effectiveness ratio for regorafenib was found to be greater than 550,000 dollars per QALY.

“The cost-effectiveness of regorafenib could be improved by the use of value-based pricing,” the authors concluded.

Reference

  1. Goldstein DA, Ahmad BB, Howard DH, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2015.61.9569. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs